For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.